FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention relates to a compound of formula I or a pharmaceutically acceptable salt thereof, where M is CR4a or N; M1 represents CR5 or N; X1 is N (R9); X2 represents O; R1 denotes H or C1-C6 alkyl; wherein each hydrogen atom in C1-C6 alkyl optionally independently substituted with deuterium, halogen, -OH, -CN, -OC1-C6 alkyl, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -NHC(O)C1-C6 alkyl, -N(C1-C6 alkyl)C(O)C1-C6 alkyl, -NHC(O)NH2, -NHC(O)NHC1-C6 alkyl, -N(C1-C6 alkyl)C(O)NH2, -N(C1-C6 alkyl)C(O)NHC1-C6 alkyl, -NHC(O)N(C1-C6 alkyl)2, -N(C1-C6 alkyl)C(O)N(C1-C6 alkyl)2, -NHC(O)OC1-C6 alkyl, -N(C1-C6 alkyl)C(O)OC1-C6 alkyl, -NHS(O)(C1-C6 alkyl), -NHS(O)2(C1-C6 alkyl), -N(C1-C6 alkyl)S(O)(C1-C6 alkyl), -N(C1-C6 alkyl)S(O)2(C1-C6 alkyl), -NHS(O)NH2, -NHS(O)2NH2, -N(C1-C6 alkyl)S(O)NH2, -N(C1-C6 alkyl)S(O)2NH2, -NHS(O)NH(C1-C6 alkyl), -NHS(O)2NH(C1-C6 alkyl), -NHS(O)N(C1-C6 alkyl)2, -NHS(O)2N(C1-C6 alkyl)2, -N(C1-C6 alkyl)S(O)NH(C1-C6 alkyl), -N(C1-C6 alkyl)S(O)2NH(C1-C6 alkyl), -N(C1-C6 alkyl)S(O)N(C1-C6 alkyl)2, -N(C1-C6 alkyl)S(O)2N(C1-C6 alkyl)2, -CO2H, -C(O)OC1-C6 alkyl, -C(O)NH2, -C(O)NH(C1-C6 alkyl), or -C(O)N(C1-C6 alkyl)2, -SC1-C6 alkyl, -S(O)C1-C6 alkyl, -S(O)2C1-C6 alkyl, -S(O)NH(C1-C6 alkyl), -S(O)2NH(C1-C6 alkyl), -S(O)N(C1-C6 alkyl)2, -S(O)2N(C1-C6 alkyl)2, -P(C1-C6 alkyl)2, -P(O)(C1-C6 alkyl)2, C3-C6 cycloalkyl or 3–7-member heterocycloalkyl; R2 and R3, together with the carbon atoms to which they are bonded, form C5-C7 cycloalkyl or 5–7-member heterocycloalkyl; or R2 and R6 together with atoms to which they are attached, form 5–7-member heterocycloalkyl, and R3 is H; each of R4, R4a and R5 independently represents H, fluor, chlorine or bromine; R6 is H, or together with R2 and atoms to which they are bonded, forms 5–7-membered heterocycloalkyl; each R9 is H; each Z1, Z4 and Z7 are N; Z2, Z3 and Z6 are CH; Z5 is -C-; n is equal to 1 or 2. Invention also relates to a method of treating and inhibiting protein- or tyrosine kinases based on said compound. 
I.
EFFECT: obtaining novel compounds which can be used in medicine for treating cancer.
17 cl
| Title | Year | Author | Number |
|---|---|---|---|
| CHIRAL DIARYL MACROCYCLES AND USE THEREOF | 2016 |
|
RU2728579C2 |
| COMBINATION THERAPY USING DIARYL MACROCYCLIC COMPOUNDS | 2018 |
|
RU2784853C2 |
| ANALOGS OF Δ12,13-ISOTAXOL, INTERMEDIATE COMPOUNDS, METHOD OF SYNTHESIS OF INTERMEDIATE COMPOUNDS AND PHARMACEUTICAL COMPOSITION | 1995 |
|
RU2142950C1 |
| PRIMARY AMINE DIAZENIUMDIOLATE HETEROCYCLIC DERIVATIVES | 2012 |
|
RU2596867C2 |
| INHIBITION OF CREB-BINDING PROTEIN (CBP) | 2019 |
|
RU2803290C2 |
| HETEROCYCLIC COMPOUNDS AND USE THEREOF FOR PREVENTING OR TREATING BACTERIAL INFECTIONS | 2016 |
|
RU2714197C2 |
| METHODS FOR OBTAINING BENZODIAZEPINE DERIVATIVES | 2018 |
|
RU2794124C2 |
| 7-HALO- AND 7β, 8β--METHANOTAXOLS, PHARMACEUTICAL COMPOSITION, INTERMEDIATE COMPOUNDS AND METHODS OF SYNTHESIS OF INTERMEDIATE COMPOUNDS | 1993 |
|
RU2125996C1 |
| DERIVATIVES OF PIPERIDINE, METHOD OF OBTAINING THEM, PHARMACEUTICAL COMPOSITION ON THEIR BASIS AND METHOD OF TREATING CHEMOKINE MEDIATED PAINFUL STATE WITH THEIR USE | 2003 |
|
RU2330019C2 |
| PESTICIDE COMPOSITIONS | 2010 |
|
RU2550352C2 |
